{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:31:00Z","timestamp":1793939460065,"version":"4.8.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02924-w","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:16:22Z","timestamp":1754266582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather"],"prefix":"10.1007","volume":"42","author":[{"given":"Sana","family":"Rahimian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Doroudian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"1","key":"2924_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/biomedicines12010123","volume":"12","author":"S Rahimian","year":"2024","unstructured":"Rahimian S, Najafi H, Afzali B, Doroudian M. Extracellular vesicles and exosomes: novel insights and perspectives on lung cancer from early detection to targeted treatment. Biomedicines. 2024;12(1):123.","journal-title":"Biomedicines"},{"issue":"8","key":"2924_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s11064-024-04157-1","volume":"49","author":"S Rahimian","year":"2024","unstructured":"Rahimian S, Najafi H, Webber CA, Jalali H. Advances in exosome-based therapies for the repair of peripheral nerve injuries. Neurochem Res. 2024;49(8):1905\u201325.","journal-title":"Neurochem Res"},{"key":"2924_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123198","volume":"358","author":"H Jalali","year":"2024","unstructured":"Jalali H, Rahimian S, Shahsavarian N, Norouzi R, Ahmadiyeh Z, Najafi H, et al. The organoid modeling approach to understanding the mechanisms underlying neurodegeneration: a comprehensive review. Life Sci. 2024;358: 123198.","journal-title":"Life Sci"},{"key":"2924_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104594","volume":"207","author":"S Rahimian","year":"2025","unstructured":"Rahimian S, Mirkazemi K, Kamalinejad A, Doroudian M. Exosome-based advances in pancreatic cancer: the potential of mesenchymal stem cells. Crit Rev Oncol Hematol. 2025;207: 104594.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"16","key":"2924_CR5","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"CE Hughes","year":"2018","unstructured":"Hughes CE, Nibbs RJ. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944\u201371.","journal-title":"FEBS J"},{"issue":"1","key":"2924_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.113.007724","volume":"66","author":"F Bachelerie","year":"2014","unstructured":"Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66(1):1\u201379.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2924_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00018-024-05445-3","volume":"81","author":"H Xu","year":"2024","unstructured":"Xu H, Li Y, Gao Y. The role of immune cells settled in the bone marrow on adult hematopoietic stem cells. Cell Mol Life Sci. 2024;81(1):420.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2924_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/ijms21030796","volume":"21","author":"AK Singh","year":"2020","unstructured":"Singh AK, Cancelas JA. Gap junctions in the bone marrow lympho-hematopoietic stem cell niche, leukemia progression, and chemoresistance. Int J Mol Sci. 2020;21(3):796.","journal-title":"Int J Mol Sci"},{"key":"2924_CR9","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3389\/fonc.2020.01672","volume":"10","author":"D Cancilla","year":"2020","unstructured":"Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and all. Front Oncol. 2020;10:1672.","journal-title":"Front Oncol"},{"key":"2924_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","volume":"9","author":"DB Pimenta","year":"2021","unstructured":"Pimenta DB, Varela VA, Datoguia TS, Caraciolo VB, Lopes GH, Pereira WO. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front Cell Dev Biol. 2021;9: 764698.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"2924_CR11","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1124\/mol.118.115477","volume":"96","author":"J Heuninck","year":"2019","unstructured":"Heuninck J, Viciano CP, I\u015fbilir A, Caspar B, Capoferri D, Briddon SJ, et al. Context-dependent signaling of CXC chemokine receptor 4 and atypical chemokine receptor 3. Mol Pharmacol. 2019;96(6):778\u201393.","journal-title":"Mol Pharmacol"},{"key":"2924_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.imlet.2019.11.007","volume":"217","author":"A Mousavi","year":"2020","unstructured":"Mousavi A. CXCL12\/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. Immunol Lett. 2020;217:91\u2013115.","journal-title":"Immunol Lett"},{"key":"2924_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01672","author":"D Cancilla","year":"2020","unstructured":"Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.01672.","journal-title":"Front Oncol"},{"issue":"3","key":"2924_CR14","first-page":"255","volume":"73","author":"EO Aboagye","year":"2023","unstructured":"Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin. 2023;73(3):255\u201374.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2924_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.bmc.2013.12.012","volume":"22","author":"GPC George","year":"2014","unstructured":"George GPC, Stevens E, \u00c5berg O, Nguyen Q-D, Pisaneschi F, Spivey AC, et al. Preclinical evaluation of a CXCR4-specific 68Ga-labelled TN14003 derivative for cancer PET imaging. Bioorg Med Chem. 2014;22(2):796\u2013803.","journal-title":"Bioorg Med Chem"},{"issue":"23","key":"2924_CR16","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.3390\/cancers13235920","volume":"13","author":"M Schottelius","year":"2021","unstructured":"Schottelius M, Herrmann K, Lapa C. In vivo targeting of CXCR4\u2014new horizons. Cancers. 2021;13(23):5920.","journal-title":"Cancers"},{"issue":"6","key":"2924_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A, H\u00e4nscheid H, L\u00fcckerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7(6):1589.","journal-title":"Theranostics"},{"issue":"1","key":"2924_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2967\/jnumed.118.210997","volume":"60","author":"C Lapa","year":"2019","unstructured":"Lapa C, H\u00e4nscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, et al. Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med. 2019;60(1):60\u20134.","journal-title":"J Nucl Med"},{"issue":"10","key":"2924_CR19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2967\/jnumed.118.223420","volume":"60","author":"S Maurer","year":"2019","unstructured":"Maurer S, Herhaus P, Lippenmeyer R, H\u00e4nscheid H, Kircher M, Schirbel A, et al. Side effects of CXC-chemokine receptor 4\u2013directed endoradiotherapy with pentixather before hematopoietic stem cell transplantation. J Nucl Med. 2019;60(10):1399\u2013405.","journal-title":"J Nucl Med"},{"issue":"8","key":"2924_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3324\/haematol.2016.142976","volume":"101","author":"P Herhaus","year":"2016","unstructured":"Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, et al. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016;101(8):932\u201340.","journal-title":"Haematologica"},{"issue":"1","key":"2924_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","volume":"10","author":"L Pagliaro","year":"2024","unstructured":"Pagliaro L, Chen S-J, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, et al. Acute lymphoblastic leukaemia. Nat Rev Dis Primers. 2024;10(1):41.","journal-title":"Nat Rev Dis Primers"},{"issue":"14","key":"2924_CR22","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.3390\/cancers14143303","volume":"14","author":"A Fallati","year":"2022","unstructured":"Fallati A, Di Marzo N, D\u2019Amico G, Dander E. Mesenchymal stromal cells (MSCs): an ally of B-cell acute lymphoblastic leukemia (B-ALL) cells in disease maintenance and progression within the bone marrow hematopoietic niche. Cancers. 2022;14(14):3303.","journal-title":"Cancers"},{"key":"2924_CR23","volume-title":"Mayo clinic proceedings","author":"S Paul","year":"2016","unstructured":"Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. In: Mayo clinic proceedings. Cham: Elsevier; 2016."},{"issue":"6","key":"2924_CR24","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577-e.","journal-title":"Blood Cancer J"},{"issue":"27","key":"2924_CR25","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"C-H Pui","year":"2015","unstructured":"Pui C-H, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938\u201348.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2924_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532\u201343.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2924_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","volume":"157","author":"JI Sive","year":"2012","unstructured":"Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG 2993 trial. Br J Haematol. 2012;157(4):463\u201371.","journal-title":"Br J Haematol"},{"issue":"3","key":"2924_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/cancers14030497","volume":"14","author":"J Marvin-Peek","year":"2022","unstructured":"Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia. Cancers. 2022;14(3):497.","journal-title":"Cancers"},{"issue":"5","key":"2924_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467\u201380.","journal-title":"Blood"},{"issue":"5","key":"2924_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.20.01564","volume":"39","author":"F Lussana","year":"2021","unstructured":"Lussana F, Gritti G, Rambaldi A. Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell\u2013redirected bispecific antibodies. J Clin Oncol. 2021;39(5):444.","journal-title":"J Clin Oncol"},{"issue":"35","key":"2924_CR31","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1200\/JCO.2017.77.3648","volume":"36","author":"R Bassan","year":"2018","unstructured":"Bassan R, Bourquin J-P, DeAngelo DJ, Chiaretti S. New approaches to the management of adult acute lymphoblastic leukemia. J Clin Oncol. 2018;36(35):3504\u201319.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2924_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","volume":"2","author":"V Cordo","year":"2021","unstructured":"Cordo V, van der Zwet JCG, Cant\u00e9-Barrett K, Pieters R, Meijerink JPP. T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies. Blood Cancer Discov. 2021;2(1):19\u201331.","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"2924_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(8):66.","journal-title":"Curr Treat Options Oncol"},{"key":"2924_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-0885-0","volume":"22","author":"E Ladikou","year":"2020","unstructured":"Ladikou E, Sivaloganathan H, Pepper A, Chevassut T. Acute myeloid leukaemia in its niche: the bone marrow microenvironment in acute myeloid leukaemia. Curr Oncol Rep. 2020;22:1\u20139.","journal-title":"Curr Oncol Rep"},{"key":"2924_CR35","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2924_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.2012.064014","volume":"98","author":"M Maynadi\u00e9","year":"2013","unstructured":"Maynadi\u00e9 M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98(2):230.","journal-title":"Haematologica"},{"issue":"3","key":"2924_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A. How i treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319\u201327.","journal-title":"Blood"},{"key":"2924_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/B978-0-12-821671-2.00039-8","volume-title":"Lanzkowsky's manual of pediatric hematology and oncology","author":"A Redner","year":"2022","unstructured":"Redner A, Kessel R. Acute myeloid leukemia. In: Lanzkowsky\u2019s manual of pediatric hematology and oncology. Elsevier; 2022. p. 439\u201358."},{"issue":"16","key":"2924_CR39","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2217\/fon-2021-1355","volume":"18","author":"TA Russell-Smith","year":"2022","unstructured":"Russell-Smith TA, Gurskyte L, Muresan B, Mamolo CM, Gezin A, Cappelleri JC, et al. Efficacy of non-intensive therapies approved for relapsed\/refractory acute myeloid leukemia: a systematic literature review. Future Oncol. 2022;18(16):2029\u201339.","journal-title":"Future Oncol"},{"issue":"1","key":"2924_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62\u201370.","journal-title":"Blood"},{"issue":"8","key":"2924_CR41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jtct.2021.05.007","volume":"27","author":"FF Yalniz","year":"2021","unstructured":"Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, et al. Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transpl Cell Ther. 2021;27(8):689\u201395.","journal-title":"Transpl Cell Ther"},{"key":"2924_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00079","volume":"8","author":"S Ghimire","year":"2017","unstructured":"Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol. 2017;8: 79.","journal-title":"Front Immunol"},{"key":"2924_CR43","first-page":"139","volume-title":"Hematopoietic stem cell transplantation for the pediatric hematologist\/oncologist","author":"C-L Kitko","year":"2017","unstructured":"Kitko C-L, Gatwood K, Connelly J. Preparing the patient for HSCT: conditioning regimens and their scientific rationale. In: Hematopoietic stem cell transplantation for the pediatric hematologist\/oncologist. Springer; 2017. p. 139\u201374."},{"issue":"10","key":"2924_CR44","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54(10):1525\u201352.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2924_CR45","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1007\/s00277-019-03820-w","volume":"98","author":"P Montesinos","year":"2019","unstructured":"Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, et al. Update on management and progress of novel therapeutics for R\/R AML: an Iberian expert panel consensus. Ann Hematol. 2019;98(11):2467\u201383.","journal-title":"Ann Hematol"},{"key":"2924_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/bs.acr.2015.04.007","volume":"127","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bhatia R. Influence of bone marrow microenvironment on leukemic stem cells: breaking up an intimate relationship. Adv Cancer Res. 2015;127:227\u201352.","journal-title":"Adv Cancer Res"},{"issue":"5","key":"2924_CR47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.37349\/etat.2024.00262","volume":"5","author":"S Khattab","year":"2024","unstructured":"Khattab S, El Sorady M, El-Ghandour A, Visani G, Piccaluga PP. Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche. Explor Target Anti-Tumor Therapy. 2024;5(5):1027.","journal-title":"Explor Target Anti-Tumor Therapy"},{"issue":"6","key":"2924_CR48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.stem.2019.10.003","volume":"25","author":"L Kunz","year":"2019","unstructured":"Kunz L, Schroeder T. A 3D tissue-wide digital imaging pipeline for quantitation of secreted molecules shows absence of CXCL12 gradients in bone marrow. Cell Stem Cell. 2019;25(6):846-54.e4.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"2924_CR49","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/10245332.2018.1486064","volume":"23","author":"A Wang","year":"2018","unstructured":"Wang A, Zhong H. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia. Hematology. 2018;23(10):729\u201339.","journal-title":"Hematology"},{"issue":"2","key":"2924_CR50","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.canlet.2015.05.007","volume":"380","author":"CR Cogle","year":"2016","unstructured":"Cogle CR, Bosse RC, Brewer T, Migdady Y, Shirzad R, Kampen KR, et al. Acute myeloid leukemia in the vascular niche. Cancer Lett. 2016;380(2):552\u201360.","journal-title":"Cancer Lett"},{"key":"2924_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174147","volume":"903","author":"Z Yaghobi","year":"2021","unstructured":"Yaghobi Z, Movassaghpour A, Talebi M, Shadbad MA, Hajiasgharzadeh K, Pourvahdani S, et al. The role of CD44 in cancer chemoresistance: a concise review. Eur J Pharmacol. 2021;903: 174147.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2924_CR52","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/stmcls\/sxae060","volume":"42","author":"SJ Sonnentag","year":"2024","unstructured":"Sonnentag SJ, Ibrahim NS, Orian-Rousseau V. CD44: a stemness driver, regulator, and marker\u2014all in one? Stem Cells. 2024;42(12):1031\u20139.","journal-title":"Stem Cells"},{"issue":"5","key":"2924_CR53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41580-019-0103-9","volume":"20","author":"S Pinho","year":"2019","unstructured":"Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol. 2019;20(5):303\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"26","key":"2924_CR54","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.2174\/1381612824666180829154119","volume":"24","author":"IA Khlusov","year":"2018","unstructured":"Khlusov IA, Litvinova LS, Khlusova MY, Yurova KA. Concept of hematopoietic and stromal niches for cell-based diagnostics and regenerative medicine (a review). Curr Pharm Des. 2018;24(26):3034\u201354.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"2924_CR55","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.3390\/ijms23084462","volume":"23","author":"O Kandarakov","year":"2022","unstructured":"Kandarakov O, Belyavsky A, Semenova E. Bone marrow niches of hematopoietic stem and progenitor cells. Int J Mol Sci. 2022;23(8):4462.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2924_CR56","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1038\/s41375-020-01062-8","volume":"34","author":"SN Hurwitz","year":"2020","unstructured":"Hurwitz SN, Jung SK, Kurre P. Hematopoietic stem and progenitor cell signaling in the niche. Leukemia. 2020;34(12):3136\u201348.","journal-title":"Leukemia"},{"issue":"3","key":"2924_CR57","volume":"69","author":"P Torres-Barrera","year":"2021","unstructured":"Torres-Barrera P, Mayani H, Ch\u00e1vez-Gonz\u00e1lez A. Understanding the hematopoietic microenvironment in chronic myeloid leukemia: a concise review. Curr Res Transl Med. 2021;69(3): 103295.","journal-title":"Curr Res Transl Med"},{"key":"2924_CR58","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fonc.2018.00444","volume":"8","author":"L Behrmann","year":"2018","unstructured":"Behrmann L, Wellbrock J, Fiedler W. Acute myeloid leukemia and the bone marrow niche\u2014take a closer look. Front Oncol. 2018;8:444.","journal-title":"Front Oncol"},{"key":"2924_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738204","volume":"12","author":"F Matteini","year":"2021","unstructured":"Matteini F, Mulaw MA, Florian MC. Aging of the hematopoietic stem cell niche: new tools to answer an old question. Front Immunol. 2021;12: 738204.","journal-title":"Front Immunol"},{"issue":"2","key":"2924_CR60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190589","volume":"217","author":"MT Witkowski","year":"2019","unstructured":"Witkowski MT, Kousteni S, Aifantis I. Mapping and targeting of the leukemic microenvironment. J Exp Med. 2019;217(2): e20190589.","journal-title":"J Exp Med"},{"issue":"1","key":"2924_CR61","first-page":"31","volume":"3","author":"SM Watt","year":"2022","unstructured":"Watt SM. The long and winding road: homeostatic and disordered haematopoietic microenvironmental niches: a narrative review. Biomater Transl. 2022;3(1):31.","journal-title":"Biomater Transl"},{"issue":"8","key":"2924_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.133","volume":"8","author":"AL Pereira","year":"2024","unstructured":"Pereira AL, Galli S, Nombela-Arrieta C. Bone marrow niches for hematopoietic stem cells. Hemasphere. 2024;8(8): e133.","journal-title":"Hemasphere"},{"issue":"5","key":"2924_CR63","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/ncb2730","volume":"15","author":"C Nombela-Arrieta","year":"2013","unstructured":"Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, et al. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol. 2013;15(5):533\u201343.","journal-title":"Nat Cell Biol"},{"key":"2924_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.798211","volume":"12","author":"N Kumar","year":"2021","unstructured":"Kumar N, Saraber P, Ding Z, Kusumbe AP. Diversity of vascular niches in bones and joints during homeostasis, ageing, and diseases. Front Immunol. 2021;12: 798211.","journal-title":"Front Immunol"},{"key":"2924_CR65","doi-asserted-by":"publisher","first-page":"1401713","DOI":"10.3389\/frhem.2024.1401713","volume":"3","author":"L Ibneeva","year":"2024","unstructured":"Ibneeva L, Grinenko T. Dissecting dormancy and quiescence in hematopoietic stem cells. Front Hematol. 2024;3:1401713.","journal-title":"Front Hematol"},{"issue":"1","key":"2924_CR66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.stem.2017.11.006","volume":"22","author":"D Duarte","year":"2018","unstructured":"Duarte D, Hawkins ED, Akinduro O, Ang H, De Filippo K, Kong IY, et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell. 2018;22(1):64-77.e6.","journal-title":"Cell Stem Cell"},{"key":"2924_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.596452","volume":"8","author":"FM Panvini","year":"2020","unstructured":"Panvini FM, Pacini S, Montali M, Barachini S, Mazzoni S, Morganti R, et al. High Nestin expression marks the endosteal capillary network in human bone marrow. Front Cell Dev Biol. 2020;8: 596452.","journal-title":"Front Cell Dev Biol"},{"key":"2924_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.574667","volume":"11","author":"Y Shi","year":"2020","unstructured":"Shi Y, Riese DJ 2nd, Shen J. The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer. Front Pharmacol. 2020;11: 574667.","journal-title":"Front Pharmacol"},{"key":"2924_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-030-62658-7_5","volume":"1302","author":"L Portella","year":"2021","unstructured":"Portella L, Bello AM, Scala S. CXCL12 signaling in the tumor microenvironment. Tumor microenvironment: the role of chemokines-part B. Adv Exp Med Biol. 2021;1302:51\u201370.","journal-title":"Adv Exp Med Biol"},{"key":"2924_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00429","volume":"6","author":"L Pawig","year":"2015","unstructured":"Pawig L, Klasen C, Weber C, Bernhagen J, Noels H. Diversity and inter-connections in the CXCR4 chemokine receptor\/ligand family: molecular perspectives. Front Immunol. 2015;6: 429.","journal-title":"Front Immunol"},{"issue":"33","key":"2924_CR71","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.2174\/0929867326666191113113110","volume":"27","author":"P Yang","year":"2020","unstructured":"Yang P, Hu Y, Zhou Q. The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer. Curr Med Chem. 2020;27(33):5543\u201361.","journal-title":"Curr Med Chem"},{"issue":"8","key":"2924_CR72","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12149-018-1290-8","volume":"32","author":"M Kircher","year":"2018","unstructured":"Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester H-J, et al. CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med. 2018;32(8):503\u201311.","journal-title":"Ann Nucl Med"},{"issue":"7","key":"2924_CR73","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.18632\/oncotarget.3217","volume":"6","author":"H Zhao","year":"2015","unstructured":"Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015;6(7):5022.","journal-title":"Oncotarget"},{"issue":"2","key":"2924_CR74","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/ijms22020843","volume":"22","author":"J Korbecki","year":"2021","unstructured":"Korbecki J, Kojder K, Kapczuk P, Kupnicka P, Gawro\u0144ska-Szklarz B, Gutowska I, et al. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors\u2014a review of literature. Int J Mol Sci. 2021;22(2):843.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2924_CR75","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.1007\/s00432-022-04444-w","volume":"149","author":"S Bao","year":"2023","unstructured":"Bao S, Darvishi M, Amin HA, Al-Haideri MT, Patra I, Kashikova K, et al. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment. J Cancer Res Clin Oncol. 2023;149(10):7945\u201368.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2924_CR76","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998335873241012161428","author":"K Sandhanam","year":"2024","unstructured":"Sandhanam K, Bhattacharjee B, Rynjah D, Kalita P, Sen S, Chakraborty R. Deciphering the interlinked CXCR4-mediated feedback loop among signaling pathways in diabetic wound healing. Curr Diabetes Rev. 2024. https:\/\/doi.org\/10.2174\/0115733998335873241012161428.","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"2924_CR77","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.3390\/ijms24044002","volume":"24","author":"O Habanjar","year":"2023","unstructured":"Habanjar O, Bingula R, Decombat C, Diab-Assaf M, Caldefie-Chezet F, Delort L. Crosstalk of inflammatory cytokines within the breast tumor microenvironment. Int J Mol Sci. 2023;24(4):4002.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2924_CR78","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7150\/thno.21397","volume":"8","author":"S Habringer","year":"2018","unstructured":"Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, et al. Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics. Theranostics. 2018;8(2):369.","journal-title":"Theranostics"},{"issue":"4","key":"2924_CR79","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001273R","volume":"35","author":"C Britton","year":"2021","unstructured":"Britton C, Poznansky M, Reeves P. Polyfunctionality of the CXCR4\/CXCL12 axis in health and disease: implications for therapeutic interventions in cancer and immune-mediated diseases. FASEB J. 2021;35(4): e21260.","journal-title":"FASEB J"},{"issue":"7","key":"2924_CR80","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/onc.2015.139","volume":"35","author":"F Guo","year":"2016","unstructured":"Guo F, Wang Y, Liu J, Mok S, Xue F, Zhang W. CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene. 2016;35(7):816\u201326.","journal-title":"Oncogene"},{"key":"2924_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/112_2020_35","volume":"178","author":"Y Xun","year":"2020","unstructured":"Xun Y, Yang H, Li J, Wu F, Liu F. CXC chemokine receptors in the tumor microenvironment and an update of antagonist development. Rev Physiol Biochem Pharmacol. 2020;178:1\u201340.","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"4","key":"2924_CR82","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.devcel.2015.03.026","volume":"33","author":"S Ivins","year":"2015","unstructured":"Ivins S, Chappell J, Vernay B, Suntharalingham J, Martineau A, Mohun TJ, et al. The CXCL12\/CXCR4 axis plays a critical role in coronary artery development. Dev Cell. 2015;33(4):455\u201368.","journal-title":"Dev Cell"},{"issue":"3","key":"2924_CR83","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/cancers13030469","volume":"13","author":"JC L\u00f3pez-Gil","year":"2021","unstructured":"L\u00f3pez-Gil JC, Martin-Hijano L, Hermann PC, Sainz B Jr. The CXCL12 crossroads in cancer stem cells and their niche. Cancers. 2021;13(3):469.","journal-title":"Cancers"},{"issue":"1","key":"2924_CR84","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324.","journal-title":"Nat Rev Immunol"},{"key":"2924_CR85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2018.03.025","volume":"113","author":"J Bandola-Simon","year":"2019","unstructured":"Bandola-Simon J, Roche PA. Dysfunction of antigen processing and presentation by dendritic cells in cancer. Mol Immunol. 2019;113:31\u20137.","journal-title":"Mol Immunol"},{"issue":"1","key":"2924_CR86","doi-asserted-by":"publisher","first-page":"17033","DOI":"10.1038\/sigtrans.2017.33","volume":"2","author":"H Guo","year":"2017","unstructured":"Guo H, Ge Y, Li X, Yang Y, Meng J, Liu J, et al. Targeting the CXCR4\/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression. Signal Transduct Target Ther. 2017;2(1):17033.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2924_CR87","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/vaccines8020164","volume":"8","author":"S Scala","year":"2020","unstructured":"Scala S, D\u2019Alterio C, Milanesi S, Castagna A, Carriero R, Farina FM, et al. New insights on the emerging genomic landscape of CXCR4 in cancer: a lesson from WHIM. Vaccines. 2020;8(2):164.","journal-title":"Vaccines"},{"issue":"17","key":"2924_CR88","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","volume":"26","author":"W Zhou","year":"2019","unstructured":"Zhou W, Guo S, Liu M, Burow ME, Wang G. Targeting CXCL12\/CXCR4 axis in tumor immunotherapy. Curr Med Chem. 2019;26(17):3026\u201341.","journal-title":"Curr Med Chem"},{"issue":"1","key":"2924_CR89","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41181-020-0091-2","volume":"5","author":"S Spreckelmeyer","year":"2020","unstructured":"Spreckelmeyer S, Schulze O, Brenner W. Fully-automated production of [68Ga]Ga-PentixaFor on the module modular lab-pharmtracer. EJNMMI Radiopharm Chem. 2020;5(1):8.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"9","key":"2924_CR90","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.7150\/thno.19119","volume":"7","author":"M Schottelius","year":"2017","unstructured":"Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, H\u00e4nscheid H, et al. [177Lu]pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent. Theranostics. 2017;7(9):2350\u201362.","journal-title":"Theranostics"},{"issue":"5","key":"2924_CR91","first-page":"754","volume":"63","author":"H H\u00e4nscheid","year":"2022","unstructured":"H\u00e4nscheid H, Schirbel A, Hartrampf P, Kraus S, Werner RA, Einsele H, et al. Biokinetics and dosimetry of 177Lu-pentixather. J Nucl Med. 2022;63(5):754\u201360.","journal-title":"J Nucl Med"},{"issue":"12","key":"2924_CR92","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.3390\/molecules28124707","volume":"28","author":"J Yu","year":"2023","unstructured":"Yu J, Zhou X, Shen L. CXCR4-targeted radiopharmaceuticals for the imaging and therapy of malignant tumors. Molecules. 2023;28(12):4707.","journal-title":"Molecules"},{"issue":"6","key":"2924_CR93","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1039\/D3CC04630C","volume":"60","author":"D de Raffele","year":"2024","unstructured":"de Raffele D, Ilie IM. Unlocking novel therapies: cyclic peptide design for amyloidogenic targets through synergies of experiments, simulations, and machine learning. Chem Commun. 2024;60(6):632\u201345.","journal-title":"Chem Commun"},{"issue":"30","key":"2924_CR94","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1039\/c2ob25107h","volume":"10","author":"S Oishi","year":"2012","unstructured":"Oishi S, Fujii N. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4). Org Biomol Chem. 2012;10(30):5720\u201331.","journal-title":"Org Biomol Chem"},{"issue":"9\u201311","key":"2924_CR95","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1515\/ract-2018-3090","volume":"107","author":"NC Okoye","year":"2019","unstructured":"Okoye NC, Baumeister JE, Khosroshahi FN, Hennkens HM, Jurisson SS. Chelators and metal complex stability for radiopharmaceutical applications. Radiochim Acta. 2019;107(9\u201311):1087\u2013120.","journal-title":"Radiochim Acta"},{"issue":"1","key":"2924_CR96","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2967\/jnumed.121.262687","volume":"63","author":"H Yang","year":"2022","unstructured":"Yang H, Wilson JJ, Orvig C, Li Y, Wilbur DS, Ramogida CF, et al. Harnessing \u03b1-emitting radionuclides for therapy: radiolabeling method review. J Nucl Med. 2022;63(1):5\u201313.","journal-title":"J Nucl Med"},{"key":"2924_CR97","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.apradiso.2013.01.039","volume":"76","author":"SR Banerjee","year":"2013","unstructured":"Banerjee SR, Pomper MG. Clinical applications of Gallium-68. Appl Radiat Isot. 2013;76:2\u201313.","journal-title":"Appl Radiat Isot"},{"issue":"3","key":"2924_CR98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1874471009666161028150654","volume":"9","author":"L Martiniova","year":"2016","unstructured":"Martiniova L, Palatis LD, Etchebehere E, Ravizzini G. Gallium-68 in medical imaging. Curr Radiopharm. 2016;9(3):187\u2013207.","journal-title":"Curr Radiopharm"},{"key":"2924_CR99","volume-title":"PubChem compound summary","author":"NCFB Information","year":"2021","unstructured":"NCFB Information. PubChem compound summary. Bethesda: National Center for Biotechnology Information; 2021."},{"key":"2924_CR100","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00259-011-2039-y","volume":"39","author":"BL Kam","year":"2012","unstructured":"Kam BL, Teunissen J, Krenning EP, de Herder WW, Khan S, Van Vliet E, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:103\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2924_CR101","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s13139-017-0505-6","volume":"52","author":"K Kim","year":"2018","unstructured":"Kim K, Kim S-J. Lu-177-based peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Nucl Med Mol Imaging. 2018;52:208\u201315.","journal-title":"Nucl Med Mol Imaging"},{"issue":"9","key":"2924_CR102","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.7150\/thno.19119","volume":"7","author":"M Schottelius","year":"2017","unstructured":"Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, H\u00e4nscheid H, et al. (177)Lu]pentixather: Comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent. Theranostics. 2017;7(9):2350\u201362.","journal-title":"Theranostics"},{"issue":"6","key":"2924_CR103","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/pharmaceutics15061733","volume":"15","author":"N Lepareur","year":"2023","unstructured":"Lepareur N, Ram\u00e9e B, Mougin-Degraef M, Bourgeois M. Clinical advances and perspectives in targeted radionuclide therapy. Pharmaceutics. 2023;15(6):1733.","journal-title":"Pharmaceutics"},{"issue":"2","key":"2924_CR104","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2967\/jnumed.115.167361","volume":"57","author":"K Herrmann","year":"2016","unstructured":"Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, H\u00e4nscheid H, et al. First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary disease. J Nucl Med. 2016;57(2):248\u201351.","journal-title":"J Nucl Med"},{"issue":"2","key":"2924_CR105","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/13543776.2020.1707186","volume":"30","author":"YA Tahirovic","year":"2020","unstructured":"Tahirovic YA, Pelly S, Jecs E, Miller EJ, Sharma SK, Liotta DC, et al. Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. Expert Opin Ther Pat. 2020;30(2):87\u2013101.","journal-title":"Expert Opin Ther Pat"},{"key":"2924_CR106","volume-title":"Exploiting chemokine receptors as targets for non-invasive imaging in cancer and immunology","author":"S Martin","year":"2024","unstructured":"Martin S. Exploiting chemokine receptors as targets for non-invasive imaging in cancer and immunology. Universit\u00e9 de Lausanne, Facult\u00e9 de biologie et m\u00e9decine; 2024."},{"issue":"12","key":"2924_CR107","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","volume":"49","author":"AK Buck","year":"2022","unstructured":"Buck AK, Serfling SE, Lindner T, H\u00e4nscheid H, Schirbel A, Hahner S, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022;49(12):4133\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2924_CR108","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","volume":"49","author":"UM Domanska","year":"2013","unstructured":"Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4\/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219\u201330.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2924_CR109","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","volume":"107","author":"JA Burger","year":"2006","unstructured":"Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107(5):1761\u20137.","journal-title":"Blood"},{"key":"2924_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-250","volume":"9","author":"SA Williams","year":"2010","unstructured":"Williams SA, Harata-Lee Y, Comerford I, Anderson RL, Smyth MJ, McColl SR. Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer. 2010;9:1\u201310.","journal-title":"Mol Cancer"},{"issue":"4","key":"2924_CR111","first-page":"291","volume":"4","author":"M Arya","year":"2004","unstructured":"Arya M, Patel HR, McGurk C, Tatoud R, Klocker H, Masters J, et al. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol. 2004;4(4):291\u2013303.","journal-title":"J Exp Ther Oncol"},{"issue":"11","key":"2924_CR112","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1096\/fj.03-0935fje","volume":"18","author":"M Darash-Yahana","year":"2004","unstructured":"Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004;18(11):1240\u20132.","journal-title":"FASEB J"},{"issue":"23","key":"2924_CR113","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.1158\/1078-0432.CCR-05-0537","volume":"11","author":"L Su","year":"2005","unstructured":"Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non\u2013small cell lung cancer cells. Clin Cancer Res. 2005;11(23):8273\u201380.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2924_CR114","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1164\/rccm.200301-071OC","volume":"167","author":"RJ Phillips","year":"2003","unstructured":"Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor\u20131\/CXCL12\u2013CXC chemokine receptor 4 biological axis in non\u2013small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167(12):1676\u201386.","journal-title":"Am J Respir Crit Care Med"},{"key":"2924_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12307-008-0016-1","volume":"2","author":"FM Speetjens","year":"2009","unstructured":"Speetjens FM, Liefers GJ, Korbee CJ, Mesker WE, van de Velde CJ, van Vlierberghe RL, et al. Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron. 2009;2:1\u20137.","journal-title":"Cancer Microenviron"},{"key":"2924_CR116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10014-010-0013-1","volume":"28","author":"M Terasaki","year":"2011","unstructured":"Terasaki M, Sugita Y, Arakawa F, Okada Y, Ohshima K, Shigemori M. CXCL12\/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol. 2011;28:89\u201397.","journal-title":"Brain Tumor Pathol"},{"key":"2924_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092314","author":"R Mezzapelle","year":"2022","unstructured":"Mezzapelle R, Leo M, Caprioglio F, Colley LS, Lamarca A, Sabatino L, et al. CXCR4\/CXCL12 activities in the tumor microenvironment and implications for tumor immunotherapy. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14092314.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2924_CR118","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1186\/s12885-022-09756-1","volume":"22","author":"L Qiu","year":"2022","unstructured":"Qiu L, Xu Y, Xu H, Yu B. The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis. BMC Cancer. 2022;22(1):681.","journal-title":"BMC Cancer"},{"issue":"5","key":"2924_CR119","volume":"1877","author":"MA Nengroo","year":"2022","unstructured":"Nengroo MA, Khan MA, Verma A, Datta D. Demystifying the CXCR4 conundrum in cancer biology: beyond the surface signaling paradigm. Biochimica et Biophysica Acta (BBA). 2022;1877(5): 188790.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"2924_CR120","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymeth.2017.09.002","volume":"130","author":"AK Buck","year":"2017","unstructured":"Buck AK, Stolzenburg A, H\u00e4nscheid H, Schirbel A, L\u00fcckerath K, Schottelius M, et al. Chemokine receptor: directed imaging and therapy. Methods. 2017;130:63\u201371.","journal-title":"Methods"},{"key":"2924_CR121","unstructured":"Miranda C. The university of hull. 2018."},{"issue":"11","key":"2924_CR122","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.bcp.2008.12.014","volume":"77","author":"E De Clercq","year":"2009","unstructured":"De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol. 2009;77(11):1655\u201364.","journal-title":"Biochem Pharmacol"},{"issue":"20","key":"2924_CR123","doi-asserted-by":"publisher","first-page":"12499","DOI":"10.3390\/ijms232012499","volume":"23","author":"M Leo","year":"2022","unstructured":"Leo M, Sabatino L. Targeting CXCR4 and CD47 receptors: an overview of new and old molecules for a biological personalized anticancer therapy. Int J Mol Sci. 2022;23(20):12499.","journal-title":"Int J Mol Sci"},{"key":"2924_CR124","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.3389\/fimmu.2018.03018","volume":"9","author":"F Eckert","year":"2018","unstructured":"Eckert F, Schilbach K, Klumpp L, Bardoscia L, Sezgin EC, Schwab M, et al. Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer. Front Immunol. 2018;9:3018.","journal-title":"Front Immunol"},{"issue":"9","key":"2924_CR125","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3348\/kjr.2023.0091","volume":"24","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gao F. Research progress of CXCR4-targeting radioligands for oncologic imaging. Korean J Radiol. 2023;24(9):871.","journal-title":"Korean J Radiol"},{"issue":"5","key":"2924_CR126","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/JLB.5BT1219-714R","volume":"109","author":"M Martin","year":"2021","unstructured":"Martin M, Mayer IA, Walenkamp AM, Lapa C, Andreeff M, Bobirca A. At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. J Leucoc Biol. 2021;109(5):953\u201367.","journal-title":"J Leucoc Biol"},{"key":"2924_CR127","volume-title":"CXCR4-directed imaging and therapy in acute leukemia","author":"S Habringer","year":"2019","unstructured":"Habringer S. CXCR4-directed imaging and therapy in acute leukemia. Technische Universit\u00e4t M\u00fcnchen; 2019."},{"issue":"3","key":"2924_CR128","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.15096","volume":"184","author":"C Lapa","year":"2019","unstructured":"Lapa C, L\u00fcckerath K, Kircher S, H\u00e4nscheid H, Grigoleit GU, Rosenwald A, et al. Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. Br J Haematol. 2019;184(3):440\u20133.","journal-title":"Br J Haematol"},{"key":"2924_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15096","author":"C Lapa","year":"2019","unstructured":"Lapa C, L\u00fcckerath K, Kircher S, H\u00e4nscheid H, Grigoleit GU, Rosenwald A, et al. Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. Br J Haematol. 2019. https:\/\/doi.org\/10.1111\/bjh.15096.","journal-title":"Br J Haematol"},{"issue":"15","key":"2924_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153814","volume":"14","author":"D Albano","year":"2022","unstructured":"Albano D, Dondi F, Bertagna F, Treglia G. The role of [68Ga] Ga-Pentixafor PET\/CT or PET\/MRI in lymphoma: a systematic review. Cancers (Basel). 2022;14(15): 3814.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2924_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13102945","volume":"13","author":"M Zamanian","year":"2024","unstructured":"Zamanian M, Albano D, Treglia G, Rizzo A, Abedi I. The clinical role of CXCR4-targeted PET on lymphoproliferative disorders: a systematic review. J Clin Med. 2024;13(10): 2945.","journal-title":"J Clin Med"},{"issue":"1","key":"2924_CR132","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/jcm13010264","volume":"13","author":"V Rodr\u00edguez-Laval","year":"2024","unstructured":"Rodr\u00edguez-Laval V, Lumbreras-Fern\u00e1ndez B, Aguado-Bueno B, G\u00f3mez-Le\u00f3n N. Imaging of multiple myeloma: present and future. J Clin Med. 2024;13(1):264.","journal-title":"J Clin Med"},{"issue":"1","key":"2924_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-023-01134-y","volume":"23","author":"M Wang","year":"2023","unstructured":"Wang M, Zhang J, Ma J, Liu L, Wang J, Zhang C. Imaging findings and clinical relevance of 68Ga-Pentixafor PET in atherosclerosis: a systematic review. BMC Med Imaging. 2023;23(1): 166.","journal-title":"BMC Med Imaging"},{"issue":"4","key":"2924_CR134","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/RLU.0000000000005657","volume":"50","author":"Z Chen","year":"2025","unstructured":"Chen Z, Liu H, Yang A, Liao J, Wu Z, Chen J, et al. 68Ga-pentixafor PET in combination with MRI improves the differential diagnosis of glioblastoma and primary central nervous system lymphoma. Clin Nucl Med. 2025;50(4):324\u201331.","journal-title":"Clin Nucl Med"},{"key":"2924_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108912","volume":"134","author":"C Hunter","year":"2024","unstructured":"Hunter C, Larimer B. Chemokine receptor PET imaging: bridging molecular insights with clinical applications. Nucl Med Biol. 2024;134: 108912.","journal-title":"Nucl Med Biol"},{"key":"2924_CR136","unstructured":"Hunter C. Diagnostic imaging approaches: pet imaging in monitoring immune responses in oncology and tuberculosis. 2024."},{"issue":"11","key":"2924_CR137","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/13543784.2024.2414119","volume":"33","author":"L Filippi","year":"2024","unstructured":"Filippi L, Ferrari C, Rubini G. Theranostic strategies in sarcoma: preliminary clinical evidence. Expert Opin Investig Drugs. 2024;33(11):1119\u201327.","journal-title":"Expert Opin Investig Drugs"},{"key":"2924_CR138","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00259-021-05196-4","volume":"49","author":"SM Jacobs","year":"2022","unstructured":"Jacobs SM, Wesseling P, de Keizer B, Tolboom N, Ververs FT, Krijger GC, et al. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68 Ga] Ga-Pentixafor\/[177 Lu] Lu-Pentixather. Eur J Nucl Med Mol Imaging. 2022;49:481\u2013491.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2924_CR139","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/978-3-031-05494-5_48","volume-title":"Radionuclide therapy of leukemias and multiple myeloma. Nuclear oncology: from pathophysiology to clinical applications","author":"M Sollini","year":"2022","unstructured":"Sollini M, Bartoli F, Galimberti S, Boni R, Erba PA. Radionuclide therapy of leukemias and multiple myeloma. Nuclear oncology: from pathophysiology to clinical applications. Springer; 2022. p. 1329\u201380."},{"issue":"1","key":"2924_CR140","doi-asserted-by":"publisher","first-page":"15284","DOI":"10.1038\/s41598-019-51754-0","volume":"9","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Ui T, Nagano A, Hino A, Arano Y. C-terminal\u2013modified LY2510924: a versatile scaffold for targeting CXC chemokine receptor type 4. Sci Rep. 2019;9(1):15284.","journal-title":"Sci Rep"},{"issue":"11","key":"2924_CR141","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1021\/acs.molpharmaceut.9b00808","volume":"16","author":"J Lau","year":"2019","unstructured":"Lau J, Kwon D, Rousseau E, Zhang Z, Zeisler J, Uribe CF, et al. [68Ga] Ga\/[177Lu] Lu-BL01, a novel theranostic pair for targeting CXC chemokine receptor 4. Mol Pharm. 2019;16(11):4688\u201395.","journal-title":"Mol Pharm"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02924-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02924-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02924-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:47:02Z","timestamp":1757335622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02924-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":141,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2924"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02924-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"402"}}